Public Sector Pension Investment Board lifted its position in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 329.9% during the third quarter, Holdings Channel reports. The firm owned 253,189 shares of the medical device company’s stock after acquiring an additional 194,296 shares during the period. Public Sector Pension Investment Board’s holdings in Globus Medical were worth $19,366,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Sanctuary Advisors LLC grew its holdings in shares of Globus Medical by 2.3% in the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after acquiring an additional 151 shares in the last quarter. Summitry LLC boosted its holdings in shares of Globus Medical by 2.6% in the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company’s stock worth $707,000 after buying an additional 211 shares during the last quarter. Central Pacific Bank Trust Division grew its position in Globus Medical by 7.8% during the third quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company’s stock valued at $229,000 after buying an additional 220 shares during the period. Arizona State Retirement System increased its holdings in Globus Medical by 0.8% during the second quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company’s stock worth $2,455,000 after buying an additional 252 shares during the last quarter. Finally, Angeles Wealth Management LLC increased its holdings in Globus Medical by 5.0% during the second quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company’s stock worth $466,000 after buying an additional 280 shares during the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research analysts have weighed in on the stock. Needham & Company LLC dropped their target price on shares of Globus Medical from $117.00 to $100.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Wall Street Zen cut shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Royal Bank Of Canada dropped their price objective on Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, October 1st. Truist Financial reduced their price objective on Globus Medical from $100.00 to $90.00 and set a “buy” rating for the company in a report on Monday, November 9th. Finally, BMO Capital Markets downgraded Globus Medical from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $94.00 to $78.00 in a research report on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $96.08.
Read Our Latest Stock Report on GMED
Globus Medical Trading Down 2.6%
Shares of GMED stock opened at $66.79 on Friday. The firm’s 50 day moving average is $75.98 and its 200 day moving average is $82.19. The stock has a market capitalization of $8.85 billion, a P/E ratio of 16.41, a PEG ratio of 1.09 and a beta of 0.98. Globus Medical, Inc. has a 12 month low of $66.63 and a 12 month high of $101.40.
Globus Medical (NYSE:GMED – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. During the same period in the previous year, the business earned $1.18 EPS. Globus Medical’s revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities analysts predict that Globus Medical, Inc. will post 4.98 EPS for the current year.
Insiders Place Their Bets
In related news, Director Ann Rhoads sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $85.00, for a total transaction of $425,000.00. Following the sale, the director directly owned 35,384 shares in the company, valued at approximately $3,007,640. The trade was a 12.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director James R. Tobin sold 41,666 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $75.16, for a total value of $3,131,616.56. Following the sale, the director directly owned 15,000 shares in the company, valued at $1,127,400. This trade represents a 73.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 76,666 shares of company stock worth $5,794,017. 18.38% of the stock is currently owned by corporate insiders.
Globus Medical Company Profile
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Read More
- Five stocks we like better than Globus Medical
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
